To test this possibility, we analyzed the levels of Shh, Ptch1, Smo, and Gli1 expression in 38 CML-CP patients, with 31 patients treated with imatinib and another 7 patients treated with hydroxycarbamide and IFNα. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.